Apimeds Pharmaceuticals US, Inc. Financial Flexibility Index
Apimeds Pharmaceuticals US, Inc. financial flexibility index. Apimeds Pharmaceuticals US, Inc. (APUS) has a Financial Flexibility Index of -0.15x as of March 2026. Free cash flow of $-2.13 Million (operating CF $-2.14 Million minus capex $9.39K) represents 0% of total liabilities ($14.70 Million). Check APUS asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Apimeds Pharmaceuticals US, Inc. (2021–2025)
Financial flexibility index of Apimeds Pharmaceuticals US, Inc. from 2021 to 2025. Historical Financial Flexibility Index trend for Apimeds Pharmaceuticals US, Inc. across 5 annual periods. Explore cash flow to debt ratio of Apimeds Pharmaceuticals US, Inc. to assess how comfortably operating cash covers total debt obligations.
Apimeds Pharmaceuticals US, Inc. Financial Flexibility Index by Year (2021–2025)
Apimeds Pharmaceuticals US, Inc. financial flexibility index by year from 2021 to 2025. Year-by-year free cash flow to debt coverage for Apimeds Pharmaceuticals US, Inc.. For the full cash flow conversion analysis, see cash efficiency ratio of Apimeds Pharmaceuticals US, Inc..
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.82x | $-8.87 Million | $-8.93 Million | $10.84 Million | ▼ -53.0% |
| 2024 | -0.53x | $-733.53K | $-733.53K | $1.37 Million | ▲ +66.7% |
| 2023 | -1.61x | $-627.79K | $-627.79K | $390.20K | ▼ -158.4% |
| 2022 | -0.62x | $-448.17K | $-448.17K | $719.78K | ▲ +68.9% |
| 2021 | -2.00x | $-823.11K | $-823.11K | $410.65K | — |